Skip to main content
. 2024 Jul 2;42(25):3033–3046. doi: 10.1200/JCO.23.02233

FIG A6.

FIG A6.

Effect on eTregs. (A) Percentage of eTregs among CD4+ T cells increased with CaboNivoIpi. (B) Higher percentage of eTregs at C3D1 was associated with better response with CaboNivo. (C) Percent eTreg/CD4 at C3D1 did not associate with OS in CaboNivoIpi treatment. (D) Higher percentage of eTregs at C3D1 was associated with better OS with CaboNivo treatment. OS, overall survival.